SCHEMBL19407355

SCHEMBL19407355

COCc1cc(C(=O)Nc2nc(-c3ccco3)c(CC3CCOCC3)s2)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLTP P55058 2/20 0.42
L3MBTL1 Q9Y468 7/20 0.40
USP2 O75604 2/20 0.40
ADORA2A P29274 4/20 0.39
ADORA1 P30542 4/20 0.39
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
POLB P06746 4/20 0.39
HPGD P15428 4/20 0.39
MEN1 O00255 4/20 0.39
MAPT P10636 4/20 0.39
KMT2A Q03164 4/20 0.39
HSD17B10 Q99714 2/20 0.39
PKM P14618 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
TP53 P04637 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19407357 0.92 PLTP (0.41) PLTPL3MBTL1USP2ADORA2AADORA1
SCHEMBL846336 0.86 ADORA2A (0.43) L3MBTL1USP2ADORA2AADORA1KDM4E
SCHEMBL19160319 0.85 ROCK2 (0.52) PLTPL3MBTL1USP2ADORA2AADORA1
SCHEMBL19407314 0.84 L3MBTL1 (0.39) L3MBTL1USP2ADORA2AADORA1KDM4E
SCHEMBL19407486 0.82 L3MBTL1 (0.44) PLTPL3MBTL1USP2ADORA2AADORA1
SCHEMBL19407504 0.82 L3MBTL1 (0.44) PLTPL3MBTL1USP2ADORA2AADORA1
SCHEMBL19407365 0.81 L3MBTL1 (0.41) PLTPL3MBTL1USP2ADORA2AADORA1
SCHEMBL19407312 0.81 L3MBTL1 (0.44) PLTPL3MBTL1USP2ADORA2AADORA1
SCHEMBL19155834 0.80 L3MBTL1 (0.41) PLTPL3MBTL1USP2ADORA2AADORA1
SCHEMBL19407320 0.79 L3MBTL1 (0.40) PLTPL3MBTL1USP2ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA KIRIN CO., LTD. (JP) 2017-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 PLTP 3318/4885L3MBTL1 699/4885USP2 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.